Ind-Swift Ltd Company History

High Court appoves the scheme of amalgamation of Swift Formulation Pvt Ltd and Mukur Pharmaceutical Company Pvt Ltd with Ind Swift Ltd.

Allottement of 1227375 equity shares to Promoters & other Bodies corporates upon the conversion of their preference shares into equity shares.

Out come of board meeting

Issuance of GDRs aggregating upto US $ 20 million

Preferential issue of upto 1.6 million equity shares at a premium of Rs 80 per share to the promoters as well as other investors

Issuance of 350000 zero coupon fully convertible warrants to the promoters

Increase in Authorised share capital of the company from Rs 100 million to Rs 150 million

Delisting of equity shares from Ahmedabad, Delhi & Jaipur Stock Exchanges

Allotment of 3,50,000 zero coupon warrants to the promoters of the company convertible into

equity shares on or before March 31, 2004.

Allotment of 12,50,000 zero coupon warrants to the bodies corporate convertible into equity shares on or before March 31, 2004.

Allotment of 3,50,000 zero coupon warrants to the promoters of the company convertible into equity shares at any time within 18 months but not before April 1, 2004.

Ind Swift Ltd ties up with Lupin Ltd for a Co-marketing pact to launch Nitazoxanide, an anti-diarrhoeal / anti-helmintic drug for the first time in India under the brand name Netazox and Nizonide respectively

Ind-Swift Laboratories Ltd. has informed that their Company has been awarded the achievement award for the Best Performing Company in Category "E" by the Express Pharma Pulse for the year 2004

Ind Swift Ltd has informed that the Company has launches a new Marketing Division under the name 'Resurgence' for Anesthesiology, Oncology and Surgery Segment

Ind Swift launches Novel Drug Delivery of Nitazoxanide

Company has splits its Face value of Shares from Rs 10 to Rs 2

Ind-Swift Limited has informed vide its letter dated March 23, 2010 that:"Pursuant to the provisions of Section 260 of The Companies Act, 1956 and Articles of Association of the company, Mr. Rishav Mehta has been appointed as Additional Director of the company".

Ind-Swift Ltd has informed that pursuant to the provisions of Section 260 of The

Companies Act, 1956 and Articles of Association of the Company, Mr. Rishav Mehta has been appointed as Additional Director of the Company.

"ROCHE DIAGNOSTICS enters into agreement with ISL to expand TROP T Rapid assay adoption in India".

"Ind-Swift in Collaboration with Wockhardt UK Limited Launches Atorvastatin Tablets in UK".

Ind Swift Labs today said it has bagged its first contract research order from a European pharmaceutical firm.

Ind-Swift Ltd has appointed Mr. V. K. Arora as an Additional Director (Non Executive, Non Promoter- independent) on the Board of Directors of the Company.